- Advertisement -
The long-awaited results of the Phase-3 trial of Covaxin that involved nearly 25,800 volunteers spanning 25 hospitals across the country is made public by Bharat Biotech. The company said the vaccine had an overall efficacy of 77.8% against symptomatic COVID.
This is higher than the overall 70.4% efficacy reported from the Phase-3 trial results of the AstraZeneca (Covishield) vaccine published in Lancet in January.
The vaccine has also shown 65.2% efficacy against the Delta variant of the coronavirus, which was behind the surge in cases in India in April and May, the Hyderabad-based pharmaceuticals major said.
